Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature
- 27 May 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Neurosurgical Review
- Vol. 27 (4), 238-245
- https://doi.org/10.1007/s10143-004-0340-y
Abstract
For recurrent and untreatable meningiomas alternative therapies, such as anti-progesterone treatment, have been sought. However, the few clinical studies have not determined progesterone receptor (PgR) expression in most cases, and studies correlating quantitative PgR expression (PgR index) with clinico-pathological variables are scarce. The aim of our study was to assess the PgR indices in a consecutive series of meningiomas and correlate these values with clinico-pathological parameters. We analyzed immunohistochemically 82 consecutive meningioma specimens (73 primary and nine recurrent tumors) for PgR and Ki-67 antigen (MIB-1). The male/female ratio was 1:1.7, and median age at the time of surgery was 57 years (range 29–77 years). The series comprised 55 grade I (subtyped as 36 meningothelial, seven fibrous, nine transitional, two psammomatous, and one angiomatous), 23 grade II, and one grade III meningiomas. Nuclear immunostaining for PgR was positive in 56 meningioma specimens (71%). PgR index was 21.4±2.8% (mean ± SE; range 0–79%). Significantly higher expression was found in male patients in the age group <50 years than in those ≥60 years and in grade I meningothelial meningiomas than in fibrous and transitional subtypes. There was a trend to lower PgR indices in non-benign meningiomas. Cell proliferation rate (MIB-1 index) was 4.4±0.4% (mean ± SE; range 0.3–15.4%). Significantly higher MIB-1 indices were found in male than female patients,in recurrent than primary and in grade II than grade I meningiomas. We observed a trend to higher PgR indices in meningiomas with MIB-1 index <5%. In sum, the highest PgR index in our series was observed in patients under the age of 50 years with WHO grade I meningiomas of the meningothelial subtype and low cell proliferation indices. If hormonal therapy has a direct action on the PgR, these patients should respond best to anti-progesterone treatment. We conclude that PgR index is variable in meningioma, depending on clinical parameters and histopathological features. Stratification of anti-progesterone therapy trials on the basis of PgR index should be considered.Keywords
This publication has 58 references indexed in Scilit:
- Progesterone receptor isoform expression in human meningiomasEuropean Journal Of Cancer, 2001
- Progesterone and Glucocorticoid Receptor Activation in MeningiomasNeurosurgery, 1995
- Estrogen and progesterone receptors in human meningiomas: Biochemical and immunocytochemical evaluationSurgical Neurology, 1995
- Expression of PDGF, PDGF-Receptor, EGF-Receptor and sex hormone receptors on meningiomaActa Neurochirurgica, 1994
- Effect of steroids and antisteroids on human meningioma cells in primary cultureJournal of Steroid Biochemistry, 1989
- Effect of the antiprogesterone RU-38486 on meningioma implanted into nude miceJournal of Neurosurgery, 1987
- Recurrence of meningiomas after operationSurgical Neurology, 1986
- Modulation of meningioma cell growth by sex steroid hormones in vitroJournal of Neurosurgery, 1985
- Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic featuresSurgical Neurology, 1983
- Estrogen-receptor protein in intracranial meningiomasJournal of Neurosurgery, 1979